Printer Friendly

CEPHALON BRIEFS STOCKHOLDERS ON RESEARCH PROGRESS, NEW DEVELOPMENTS

    CEPHALON BRIEFS STOCKHOLDERS ON RESEARCH PROGRESS, NEW DEVELOPMENTS
    NEW YORK, Nov. 18 /PRNewswire/ -- At Cephalon, Inc.'s (NASDAQ: CEPH) annual meeting held here today, Dr. Frank Baldino, Jr., Cephalon president and CEO, revealed a new research program focusing on neurodegenerative diseases of the retina; announced the signing of an agreement with the Salk Institute of Biotechnology/Industrial Associates, Inc. (SIBIA); and presented research data on IGF-1 (Insulin-like Growth Factor (Myotrophin(TM)) for the treatment of amyotrophic lateral sclerosis (ALS).
    Baldino announced that the company has identified a family of small peptides that promote the survival of photoreceptor cells in the retina. Retinopathies are characterized by the loss of specialized neurons in the retina responsible for vision, resulting in visual impairment and blindness.  Loss of photoreceptor cells occurs in over 90 percent of the patients diagnosed with retinal disease today.  By the year 2000, age-related retinopathy could affect over 6 million people.  The company has filed a patent application for the use of these molecules in the treatment of retinopathy.  Research performed at Cephalon indicates these molecules look very promising as potential therapeutics.
    The company also announced it has entered into an agreement with SIBIA for human recombinant IGF-1.  "This arrangement with SIBIA will provide Cephalon with sufficient GMP grade product to complete the clinical trials of Myotrophin, and in the longer term allow the company to license the technology for manufacturing purposes," stated Baldino.
    Last week at the Society for Neuroscience meeting in New Orleans, the company presented data showing enhanced motor neuron sprouting in response to subcutaneously administered IGF-1 treatment.  In neurodegenerative diseases such as ALS, this effect may permit healthy motor neurons to reconnect to the compromised muscle tissue and enhance muscle function.  This type of therapeutic response would also be beneficial in a variety of peripheral neuropathies.
    Earlier this fall the company announced receipt of a notice of allowance from the U.S. Patent Office for their patent for the use of IGF-1 in the treatment of ALS.
    Cephalon, Inc. was founded in 1987 to discover, develop and commercialize novel therapeutic products for the treatment of stroke and neurodegenerative disorders including ALS and Alzheimer's disease.
    -0-      11/18/91
    /CONTACT:  Nicole Vitullo of Cephalon, 215-344-0200/
    (CEPH) CO:  Cephalon, Inc. ST:  Pennsylvania IN:  MTC SU: JT -- NY003 -- 1205 11/18/91 08:01 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 18, 1991
Words:386
Previous Article:KMART CORPORATION REPORTS THIRD-QUARTER SALES AND EARNINGS
Next Article:GRANITE LOW BIDDER ON $50 MILLION TEXAS HIGHWAY JOB
Topics:


Related Articles
CEPHALON REPORTS PROGRESS ON ALZHEIMER'S DISEASE RESEARCH
CEPHALON REPORTS PROGRESS ON ALZHEIMER'S DISEASE RESEARCH
CEPHALON, INC. RECEIVES SBIR GRANT FROM THE NIH TO RESEARCH NOVEL THERAPEUTICS FOR BRAIN AND SPINAL CORD NERVE DAMAGE AND DEGENERATION
CEPHALON ANNOUNCES 1992 FINANCIAL RESULTS
CEPHALON REPORTS THIRD QUARTER RESULTS
CEPHALON AND SCHERING-PLOUGH RENEW ALZHEIMER'S DISEASE RESEARCH COLLABORATION
Cephalon and TAP Launch Phase I Cancer Study
Cephalon Reports First Quarter Results
Cephalon Reports First Quarter Results
Cephalon, Inc. and CIMA LABS INC. Announce Agreement in Principle with FTC Staff on Proposed Merger.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters